Combination Drug Formulation & Single-Entity Evaluation Support

This contract involves the development and pricing of fixed-dose combination drugs, with a specific focus on supporting the Defense Health Agency’s evaluation process for single-entity drugs used in substitution and pricing determinations. The work centers on formulating combination drug products and assisting with their assessment to ensure appropriate pricing under the DHA’s guidelines. The contract is classified as a subcontract under NAICS code 325412, which pertains to pharmaceutical preparation manufacturing. The contract was posted on May 7, 2026, with a response deadline of June 29, 2026, 5:00 PM. The place of performance is located in San Antonio, with the contracting agency being the Defense Health Agency under the Department of Defense. Key details such as the solicitation number, point of contact, and specific organization type are not provided. This contract aims to streamline drug substitution and pricing by leveraging evaluation support services related to combination drugs critical to healthcare delivery within the Department of Defense system.